Breakthrough Pill Doubles Survival for Pancreatic Cancer | Colorado Springs News

FDA just approved a groundbreaking daily pill, Rasonque, for advanced pancreatic cancer — a disease long considered nearly untreatable. Targeting the elusive KRAS mutation, this drug nearly doubled median survival from 6.7 to 13.2 months in trials, with doctors calling it the best option yet. Public attention, sparked by a former senator’s TV testimony, helped accelerate approval by over six months. The “undruggable” KRAS protein is now beatable — and this breakthrough could unlock new treatments for lung cancer and beyond. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/b52828405ac32904